INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Garner Thomas reported ACAD

EVP, Chief Commercial Officer · ACADIA PHARMACEUTICALS INC · ACADIA PHARMACEUTICALS INC — Restricted Stock Units

Side
A
Value
—
Shares
28.5K
Price
—
Executed
Mar 6, 2026
Disclosed
Mar 10, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 6 executedMar 10, 2026 disclosed

ACAD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ACAD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    16
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Grant or award
    		A—
    6,815 sh
    		Oct 15, 2026Oct 30, 2026
    traded Oct 15, 2026
    		+15dSEC FORM 4

    Evidence

    17
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Open-market sale
    		SELL$69K
    3,321 sh
    		Oct 30, 2026Oct 30, 2026
    traded Oct 30, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$145K
    5,000 sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    6
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M$255K
    14.3K sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    2
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M$104K
    5,849 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    8
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$170K
    5,849 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    8
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$273K
    9,292 sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    0
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M—
    5,849 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SC
    Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Option exercise · 10b5-1 plan
    		M—
    14.3K sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    15
    KJ
    Kihara JamesPRINCIPAL ACCOUNTING OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Open-market sale · 10b5-1 plan
    		SELL$298K
    11.4K sh
    		Jun 26, 2026Jun 29, 2026
    traded Jun 26, 2026
    		+3dSEC FORM 4

    Evidence

    17
    NA
    Ndu AdoraDirector
    ACADACADIA PHARMACEUTICALS INC
    Option exercise
    		M—
    8,107 sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    9
    NA
    Ndu AdoraDirector
    ACADACADIA PHARMACEUTICALS INC
    Option exercise
    		M—
    8,107 sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    9
    NA
    Ndu AdoraDirector
    ACADACADIA PHARMACEUTICALS INC
    Grant or award
    		A—
    16.0K sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    9
    NA
    Ndu AdoraDirector
    ACADACADIA PHARMACEUTICALS INC
    Grant or award
    		A—
    9,311 sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    9
    GA
    Garofalo Elizabeth A.Director
    ACADACADIA PHARMACEUTICALS INC
    Grant or award
    		A—
    16.0K sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    9
    GA
    Garofalo Elizabeth A.Director
    ACADACADIA PHARMACEUTICALS INC
    Grant or award
    		A—
    9,311 sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    9
    GA
    Garofalo Elizabeth A.Director
    ACADACADIA PHARMACEUTICALS INC
    Option exercise
    		M—
    8,107 sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    17
    GA
    Garofalo Elizabeth A.Director
    ACADACADIA PHARMACEUTICALS INC
    Option exercise
    		M—
    8,107 sh
    		May 29, 2026Jun 1, 2026
    traded May 29, 2026
    		+3dSEC FORM 4

    Evidence

    5
    KJ
    Kihara JamesPRINCIPAL ACCOUNTING OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Option exercise
    		M—
    2,010 sh
    		Apr 5, 2026Apr 7, 2026
    traded Apr 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KJ
    Kihara JamesPRINCIPAL ACCOUNTING OFFICER
    ACADACADIA PHARMACEUTICALS INC
    Option exercise
    		M—
    2,010 sh
    		Apr 5, 2026Apr 7, 2026
    traded Apr 5, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001996325-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 6, 2026
    Published
    Mar 10, 2026
    Ingested by INSIDER
    Nov 5, 04:12 UTC
    Last re-read
    Nov 5, 04:12 UTC

    Extracted facts

    Filer
    Garner Thomas
    Role
    EVP, Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ACADIA PHARMACEUTICALS INC — Restricted Stock Units
    Ticker
    ACAD
    Shares
    28.5K
    Price per share
    $0
    Execution date (reported)
    Mar 6, 2026
    Owned after transaction
    28.5K shares
    Days from execution to publication
    4

    What this establishes

    Garner Thomas filed this Form 4 reporting a grant or award of ACAD on Mar 6, 2026. It became public on Mar 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, Chief Commercial Officer
    Garner Thomascik:0001996325
    Issuer
    ACADIA PHARMACEUTICALS INCcik:0001070494

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.